Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis
- Conditions
- Tuberculosis
- Interventions
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2018-11-08
- Target Recruit Count
- 70
- Registration Number
- NCT00396084
- Locations
- 🇺🇸
San Francisco General Hospital - Pulmonary and Critical Care Medicine, San Francisco, California, United States
🇧🇷Universidade Federal do Espirito Santo - Duke Hubert-Yeargan Center, Vitória, Espírito Santo, Brazil
A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women
- Conditions
- Anemia
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- AMAG Pharmaceuticals, Inc.
- Target Recruit Count
- 174
- Registration Number
- NCT00360425
Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose
- Conditions
- Eye InfectionInfection
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2006-07-04
- Lead Sponsor
- Ophthalmic Consultants of Boston
- Target Recruit Count
- 40
- Registration Number
- NCT00347828
- Locations
- 🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis
- Conditions
- Acute Bacterial Conjunctivitis
- Interventions
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 1161
- Registration Number
- NCT00348348
Local Moxifloxacin and Povidone Iodine Versus Povidone Iodine Alone as a Prophylaxis Before Eye Operations
- Conditions
- Eye Infections
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2007-06-01
- Lead Sponsor
- HaEmek Medical Center, Israel
- Target Recruit Count
- 500
- Registration Number
- NCT00335088
- Locations
- 🇮🇱
Ophthalmology Department, HaEmek Medical Center, Afula, Israel, Afula, Israel
AL-15469A for the Treatment of Bacterial Conjunctivitis
- Conditions
- Bacterial Conjunctivitis
- Interventions
- First Posted Date
- 2006-06-01
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 695
- Registration Number
- NCT00332293
- Locations
- 🇺🇸
Contact Alcon for Trial Locations, Fort Worth, Texas, United States
Efficacy/Safety of Antibiotic Steroid Combination in Prevention of Postoperative Inflammation in Cataract Surgery
- Conditions
- Inflammation Following Cataract Surgery
- Interventions
- Drug: antibiotic/steroid combination
- First Posted Date
- 2006-05-29
- Last Posted Date
- 2009-08-07
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 132
- Registration Number
- NCT00331084
- Locations
- 🇧🇷
Dept of Opthalmology - Rua Botucatu 824, São Paulo, SP, Brazil
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
- Conditions
- Breast CancerChronic Myeloproliferative DisordersGestational Trophoblastic TumorLeukemiaTesticular Germ Cell TumorInfectionMultiple Myeloma and Plasma Cell NeoplasmLymphomaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-05-11
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 240
- Registration Number
- NCT00324324
- Locations
- 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
- First Posted Date
- 2006-04-10
- Last Posted Date
- 2012-11-02
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 137
- Registration Number
- NCT00312338
- Locations
- 🇺🇸
Multiple Locations, Fort Worth, Texas, United States
Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 71
- Registration Number
- NCT00310596
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.